| |  Online-Ressource |
|---|
| Verfasst von: | Schneeweiss, Andreas [VerfasserIn]  |
|---|
| | Hensel, Manfred [VerfasserIn] |
|---|
| | Goerner, Ronald [VerfasserIn] |
|---|
| | Khbeis, Tanja [VerfasserIn] |
|---|
| | Hohaus, Stefan [VerfasserIn] |
|---|
| | Egerer, Gerlinde [VerfasserIn] |
|---|
| | Solomayer, Erich-Franz [VerfasserIn] |
|---|
| | Haas, R. [VerfasserIn] |
|---|
| | Grischke, Eva-Maria [VerfasserIn] |
|---|
| | Bastert, Gunther [VerfasserIn] |
|---|
| | Ho, Anthony Dick [VerfasserIn] |
|---|
| Titel: | Comparison of double and triple high-dose chemotherapy with autologous blood stem cell transplantation in patients with metastatic breast cancer |
|---|
| Verf.angabe: | A. Schneeweiss, M. Hensel, R. Goerner, T. Khbeis, S. Hohaus, G. Egerer, E. Solomayer, R. Haas, E.-M. Grischke, G. Bastert, A. D. Ho |
|---|
| E-Jahr: | 2001 |
|---|
| Jahr: | [2001] |
|---|
| Umfang: | 10 S. |
|---|
| Fussnoten: | Elektronische Reproduktion der Druckausgabe ; Gesehen am 21.12.2021 |
|---|
| Titel Quelle: | Enthalten in: Stem cells |
|---|
| Ort Quelle: | Hoboken, NJ : Wiley-Blackwell, 1983 |
|---|
| Jahr Quelle: | 2001 |
|---|
| Band/Heft Quelle: | 19(2001), 2, Seite 151-160 |
|---|
| ISSN Quelle: | 1549-4918 |
|---|
| Abstract: | In patients with metastatic breast cancer (MBC), early dose intensification with multiple cycles of peripheral blood stem cell-supported high-dose chemotherapy (HDCT) seems superior to a late dose-intensification strategy. We compared the progression-free survival (PFS) and overall survival (OS) of 20 patients treated with a double (D)-HDCT regimen to 20 patients who received a triple (T)-HDCT, matched by age, estrogen receptor (ER) status, adjuvant chemotherapy, initial disease-free interval, predominant metastatic site, and number of metastatic sites. At a median follow-up of 41.5 months (range, 14-88 months) an intent-to-treat analysis showed no difference in PFS (p = 0.72) and OS (p = 0.93) between the matched patients. For all 76 patients treated within the D- or T-HDCT trial, median PFS and OS was 13 months (range, 2-78 months) and 24.5 months (range, 7-78 months), respectively. In multivariate analysis independent predictors of shorter OS included negative ER (relative risk [RR] = 3.0 [95% confidence interval (CI) 1.5-5.9]; p = 0.002), more than two metastatic sites (RR = 2.4 [95% CI 1.0-5.7]; p = 0.049) and failure to achieve complete remission/no evidence of disease (CR/NED) after HDCT (RR = 4.5 [95% CI 2.0-10.1]; p < 0.0001). These data show that early dose intensification with T-HDCT is not superior to a D-HDCT regimen in patients with MBC. ER-negative tumors, more than two metastatic sites and no CR/NED after HDCT, are associated with inferior outcome. |
|---|
| DOI: | doi:10.1634/stemcells.19-2-151 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext ; Verlag: https://doi.org/10.1634/stemcells.19-2-151 |
|---|
| | Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1634/stemcells.19-2-151 |
|---|
| | DOI: https://doi.org/10.1634/stemcells.19-2-151 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | Blood stem cell transplantation |
|---|
| | High-dose chemotherapy |
|---|
| | Metastatic breast cancer |
|---|
| | Multiple cycle |
|---|
| K10plus-PPN: | 1782655085 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Comparison of double and triple high-dose chemotherapy with autologous blood stem cell transplantation in patients with metastatic breast cancer / Schneeweiss, Andreas [VerfasserIn]; [2001] (Online-Ressource)
